Javier San Martin
Plus aucun poste en cours
Fortune : 6 M $ au 29/02/2024
Profil
Javier San Martin is former Chief Medical Officer at Arrowhead Pharmaceuticals, Inc., former Executive Director-Bone Therapeutic Area at Amgen, Inc., former Principal at Eli Lilly & Co., former Senior VP & Head-Global Clinical Development at Ultragenyx Pharmaceutical, Inc. and former Senior Vice President-Clinical Development at Lundbeck Seattle BioPharmaceuticals, Inc.
He received a doctorate from the University of Buenos Aires School of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
10/01/2024 | 198 497 ( 0,16% ) | 6 M $ | 29/02/2024 |
Anciens postes connus de Javier San Martin
Sociétés | Poste | Fin |
---|---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2024 |
ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/11/2019 |
AMGEN INC. | Corporate Officer/Principal | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Javier San Martin
University of Buenos Aires School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
AMGEN INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |